Seres Health, Inc., a Cambridge, MA-based microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, completed a $65m Series D financing.
The round was led by Nestle Health Science, a wholly-owned subsidiary of Nestle. In connection with the investment, Nestle Health Science’s CEO, Greg Behar, joined the Seres Board of Directors.
The company intends to use the funds for the further development of its lead product candidate, SER-109, for preventing the recurrence of Clostridium difficile infection, into Phase 3 clinical trials as well as the advancement of its pipeline of therapeutics to treat other diseases of the human microbiome.
Led Dr. Roger J. Pomerantz, President, CEO and Chairman, Seres is developing the Ecobiotic® therapeutic products, novel drugs to treat diseases by targeting the underlying biology of the human microbiome. Current product candidates span infectious, metabolic, and inflammatory diseases.